Clinical Trial Update: Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating antiviral activity, safety, and pharmacokinetics of repeated doses of JNJ 53718678 for respiratory syncytial virus infection has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• JNJ-53718678

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED